Physician profile
Amod Jain
NPI 1316047012
$2,455.56
in general payments reported to CMS, 2019-2025
15 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $48.32 · 2021: $125 · 2022: $459 · 2023: $254 · 2024: $692 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $450.86 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $272.33 | 2020-2022 | |
| Genzyme Corporation | $265.22 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $243.43 | 2022-2024 | |
| Madrigal Pharmaceuticals | $147.32 | 2025 | Rezdiffra |
| Orphalan INC | $141.72 | 2024 | Cuvrior |
| Gilead Sciences, INC. | $131.94 | 2025 | Livdelzi |
| Regeneron Pharmaceuticals, INC. | $128.70 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $126.67 | 2024 | Entyvio |
| Ferring Pharmaceuticals INC. | $125.10 | 2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Novo Nordisk INC | $124.89 | 2025 | |
| Boston Scientific Corporation | $104.68 | 2019 | |
| Exelixis INC. | $39.06 | 2019 | |
| Celltrion USA INC. | $28.64 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amod Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.